Combination of pioglitazone and dendritic cell to optimize efficacy of immune cell therapy in CT26 tumor models

Samaneh Tokhanbigli ¹ , Helia Alavifard ¹ , Hamid Asadzadeh Aghdaei ¹, Mohammad Reza Zali ², Kaveh Baghaei ¹ *

Cited by CrossRef: 4

1- Aluru S, Thyagarajan A, Sahu R. Pioglitazone-Based Combination Approaches for Non-Small-Cell Lung Cancer. Pharmaceutics. 2025;17(11):1416 [Crossref]

2- Reichling J, Li B, Yu Y, Gutting T, Weidner P, Sticht C, Ebert M, Burgermeister E. PPARγ activation sensitizes MSS gastrointestinal cancer cells to PD1 blockage. Cancer Treatment and Research Communications. 2026;48:101309 [Crossref]

3- Kounatidis D, Vallianou N, Karampela I, Rebelos E, Kouveletsou M, Dalopoulos V, Koufopoulos P, Diakoumopoulou E, Tentolouris N, Dalamaga M. Anti-Diabetic Therapies and Cancer: From Bench to Bedside. Biomolecules. 2024;14(11):1479 [Crossref]

4- Wang D, Zhang Z, Li X, He L. RNA binding protein PUM2 promotes IL-1β-induced apoptosis of chondrocytes via regulating FOXO3 expression. Heliyon. 2024;10(3):e25080 [Crossref]

5- Wen J, Wu L, Zhong S, Shan H, Luo J. The role of GPI-anchored LY6/uPAR family proteins in connecting membrane microdomains with immune regulation and diseases. Critical Reviews in Oncology/Hematology. 2025;216:104971 [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate (2024): 19%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded; Google Scholar; SJR; Essential Science Indicators; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO
Member of
Follower of ICMJE
Permission: Creative Commons